$EW (Edwards Lifesciences Corp.)

$EW {{ '2016-04-27T11:26:07+0000' | timeago}} • Webcast

In 1Q16, $EW recorded $12.2MM in intellectual property-related expenses. Reported tax rate was 22% in the quarter. FX rates decreased 1Q16 sales by $9MM versus 1Q15. At current rates, company estimates minimal FX impact to 2016 sales versus 2015. FX rate had less than a $0.01 impact on EPS in 1Q16.

$EW {{ '2017-11-06T18:42:20+0000' | timeago}} • Webcast

In Sept. 2017, $EW decided to close its manufacturing plant in Switzerland in early 2018. The company has recorded $10.2MM charge relating to severance and other costs related to this closure. This decision is would impact 232 employees. Substantial part of the severance obligations ($9.6MM) are expected to be paid by Sept. 2018.

$EW {{ '2017-11-06T18:42:07+0000' | timeago}} • Webcast

$EW expects the transcatheter aortic valve replacement (TAVR) market is worth $5Bil by 2021. The company expects its premium self-expanding valve CENTERA to be launched in Europe by end of 2017. In Europe, it had launched aortic valve INSPIRIS RESILIA in first quarter and is slated for US launch in 2018, as it was approved by FDA in July 2017.

$EW {{ '2017-10-25T19:52:37+0000' | timeago}} • Announcement

$EW's 3Q sales grew 11% to $821.5MM, driven primarily by its Transcatheter Heart Valve Therapy (THVT) segment. THVT, which is the money spinner for the firm, sales grew 17% to $481MM vs. 3Q16, but were down sequentially from $488MM in 2Q17. The company expects its THVT unit to earn $5Bil by 2021.

$EW {{ '2017-10-24T22:23:28+0000' | timeago}} • Infographic

$EW Edwards Lifesciences Earnings AlphaGraphics: Q3 2017 highlights

$EW {{ '2017-07-26T20:43:20+0000' | timeago}} • Announcement

For 3Q17, $EW projects underlying sales, adjusting for the impact of Germany stocking sales consumption, to be between $810-850MM, and adjusted earnings per share of $0.80 to $0.90.

$EW {{ '2017-07-26T20:42:56+0000' | timeago}} • Announcement

For FY17, $EW's full year sales estimate is now at the high end of its previous $3.2-3.4Bil guidance. Edwards Lifesciences Corp is also raising its estimate for FY17 adjusted earnings per share to $3.65-3.85, from $3.43-3.55.

$EW {{ '2017-07-26T20:40:21+0000' | timeago}} • Announcement

With strong demand for TAVR therapy resulted in total sales growth of 15% on an underlying basis, $EW's 2Q17 sales soared 11% to $841.8MM. Net income for the quarter jumped 47% to $186.1MM or $0.86 per diluted share. Adjusted earnings per share grew 42.1% to $1.08 while underlying sales rose 15% to about $864MM.

$EW {{ '2017-04-25T23:07:05+0000' | timeago}} • Webcast

In terms of the enrollment for low risk trial PARTNER III, $EW said it had a slow start in 2016, but is hopeful to get fully enrolled by the end of 2017.

$EW {{ '2017-04-25T21:11:05+0000' | timeago}} • Announcement

$EW expects its 2Q17 sales, excluding the impact of Germany stocking sales, to be about $810-850MM. Adjusted EPS is expected to be about $0.82-0.92.

$EW {{ '2017-04-25T21:09:18+0000' | timeago}} • Announcement

For FY17, $EW is narrowing its sales guidance to $3.2-3.2MM, from $3.0-3.4Bil. The company also raised its guidance for adjusted EPS to $3.43-3.55, from $3.30-3.45.

$EW {{ '2017-04-25T21:04:16+0000' | timeago}} • Announcement

Medical device maker $EW 1Q17 earnings rose 61% to $230.2MM or $1.06 per share, compared to $143MM, or $0.66 per share during 1Q16. Sales rose 26.7% YoY to $883.5MM. Excluding items, $EW earned $0.94, up 32%.

$PSA {{ '2017-02-23T13:58:17+0000' | timeago}} • Announcement

$PSA has appointed Leslie Heisz as an independent trustee of its Board of Trustees, effective February 23, 2017. Heisz's appointment expands the board to nine trustees, six of whom are independent. She currently serves on the boards of Kaiser Permanente and $EW.

$EW {{ '2017-02-02T00:00:03+0000' | timeago}} • Webcast

For 2017, $EW expects Transcatheter Heart Valve Therapy sales of $1.7-2Bil. For Surgical Heart Valve Therapy, the company expects sales of $750-790MM and for Critical Care, sales are expected to be $560-600MM.

$EW {{ '2017-02-01T23:48:47+0000' | timeago}} • Webcast

In 4Q16, $EW’s Critical Care sales were $146.3MM, representing an increase of 4.1% versus last year, or 2.5% on an underlying basis. Growth was driven by its Enhanced Surgical Recovery Program in the US and developing markets. In 2017, $EW expects underlying sales growth for Critical Care to be 5-7%.

$EW {{ '2017-02-01T23:45:27+0000' | timeago}} • Webcast

$EW's Surgical Heart Valve Therapy sales for 4Q16 were $189MM, down 4% compared to last year, driven by lower aortic valve sales in the US and Europe. Surgical heart valve sales were lower, primarily due to the impact of SAPIEN 3 and continued constrained mitral supply.

$EW {{ '2017-02-01T23:37:13+0000' | timeago}} • Webcast

During 4Q16, $EW’s Transcatheter Heart Valve sales in the US were $267MM and grew 41% on an underlying basis versus the prior year. Outside the US, underlying THV sales grew 19%. The company estimates total TAVR procedure growth in Europe was approx. 15% in 4Q16 compared to last year.

$EW {{ '2017-02-01T22:17:31+0000' | timeago}} • Announcement

$EW still expects 2017 sales of $3.0-3.4Bil and adjusted EPS of $3.30-3.45. For 1Q17, $EW expects sales of $760-800MM and adjusted EPS of $0.79-0.89.

$EW {{ '2017-02-01T22:15:49+0000' | timeago}} • Announcement

$EW's Transcatheter Heart Valve Therapy (THVT) sales for 4Q16 was $432MM, a 29.2% growth rate over 4Q15, or 31.8% on an underlying basis. Growth was led by continued strong therapy adoption across all geographies, with notable strength in the U.S. and Japan.

$EW {{ '2017-02-01T22:15:32+0000' | timeago}} • Announcement

$EW reported a rise in 4Q16 earnings driven by higher sales and strong adoption of transcatheter aortic valve replacement (TAVR) therapy. Net income rose to $158.5MM or $0.73 per share from $140.7MM or $0.64 per share last year. Net sales grew to $767.7MM from $671.1MM. Adjusted EPS increased to $0.75 from $0.64.

$EW {{ '2016-10-25T22:39:42+0000' | timeago}} • Webcast

During 3Q16, $EW generated free cash flow of $158MM. This is defined as cash flow from operating activities of $206MM, less capital investments of $48MM. At the end of 3Q16, the company had cash, cash equivalents and short-term investments of approx. $1.2Bil. Total debt was approx. $600MM.

Recent Transcripts

ENDP (Endo International plc)
Thursday, November 9 2017 - 9:30pm
JCI (Johnson Controls Inc.)
Thursday, November 9 2017 - 4:00pm
VRML (Vermillion, Inc.)
Wednesday, November 8 2017 - 9:30pm
IVC (Invacare Corporation)
Wednesday, November 8 2017 - 1:30pm
CCXI (ChemoCentryx, Inc.)
Tuesday, November 7 2017 - 10:00pm
ATRS (Antares Pharma Inc.)
Tuesday, November 7 2017 - 1:30pm
XRAY (DENTSPLY International Inc.)
Friday, November 3 2017 - 12:30pm
HRC (Hill-Rom Holdings, Inc.)
Friday, November 3 2017 - 12:00pm
MTD (Mettler-Toledo International Inc.)
Thursday, November 2 2017 - 9:00pm
LIVN (LivaNova PLC)
Thursday, November 2 2017 - 1:00pm
WMGI (Wright Medical Group N.V.)
Wednesday, November 1 2017 - 8:30pm
STE (Steris Plc)
Wednesday, November 1 2017 - 2:00pm
AGN (Allergan plc)
Wednesday, November 1 2017 - 12:30pm
AMRN (Amarin Corporation plc)
Wednesday, November 1 2017 - 12:00pm
MASI (Masimo Corporation)
Tuesday, October 31 2017 - 8:30pm
IDXX (IDEXX Laboratories, Inc.)
Tuesday, October 31 2017 - 12:30pm
CRY (CryoLife Inc.)
Tuesday, October 31 2017 - 12:00pm
ABBV (AbbVie Inc.)
Friday, October 27 2017 - 1:00pm
KAMN (Kaman Corporation)
Friday, October 27 2017 - 12:30pm
MTRN (Materion Corporation)
Thursday, October 26 2017 - 1:00pm

AlphaGraphics you may like